A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity

Biochimie

Volumn 91, Issue 8, 2009, Pages 996-1002

  Dourlat, Jennifer ^a,b   Liu, Wang Qing ^a,b   Sancier, Florence ^c   Edmonds, Thomas ^c   Pamonsinlapatham, Perayot ^a,b   Cruzalegui, Francisco ^c   Garbay, Christiane ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Cellular effects; Immunofluorescence; Peptide inhibitor; STAT3

Indexed keywords

ALANYLTYROSYLARGINYLASPARAGINYLARGINYLPHOSPHOTYROSYLARGINYLARGINYLGLUTAMINYLTYROSYLARGINYLTYROSINE; ALANYLTYROSYLARGINYLASPARAGINYLARGINYLPHOSPHOTYROSYLARGINYLARGINYLGLUTAMINYLTYROSYLARGINYLTYROSINE 6 AMINO HEXANOIC ACID ANTENNAPEDIA PROTEIN; ANTENNAPEDIA PROTEIN; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; ARGINYLASPARAGINYLARGINYLTYROSYLARGINYLARGINYLGLUTAMINYLTYROSYLARGINYLTYROSINE 6 AMINO HEXANOIC ACID ANTENNAPEDIA PROTEIN; CELL CYCLE PROTEIN; PHOSPHOPEPTIDE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN 3T3; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DIMERIZATION; DRUG POTENCY; IC 50; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DNA; DOWN-REGULATION; MICE; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; PHOSPHOPEPTIDES; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN TRANSPORT; SRC HOMOLOGY DOMAINS; STAT3 TRANSCRIPTION FACTOR;

EID: 67649424632     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2009.05.006     Document Type: Article

References (45)

1. Zhong Z., Wen Z., and Darnell Jr. J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264 (1994) 95-98
2. Darnell Jr. J.E. STATs and gene regulation. Science 277 (1997) 1630-1635
3. Levy D.E., and Darnell Jr. J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell. Biol. 3 (2002) 651-662
4. Reddy E.P., Korapati A., Chaturvedi P., and Rane S. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene 19 (2000) 2532-2547
5. Darnell Jr. J.E., Kerr I.M., and Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994) 1415-1421
6. Berclaz G., Altermatt H.J., Rohrbach V., Siragusa A., Dreher E., and Smith P.D. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int. J. Oncol. 19 (2001) 1155-1160
7. Leong P.L., Andrews G.A., Johnson D.E., et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4138-4143
8. Dhir R., Ni Z., Lou W., DeMiguel F., Grandis J.R., and Gao A.C. Stat3 activation in prostatic carcinomas. Prostate 51 (2002) 241-246
9. Catlett-Falcone R., Landowski T.H., Oshiro M.M., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 (1999) 105-115
10. Niu G., Bowman T., Huang M., et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21 (2002) 7001-7010
11. Bromberg J.F., Wrzeszczynska M.H., Devgan G., et al. Stat3 as an oncogene. Cell 98 (1999) 295-303
12. Leslie K., Lang C., Devgan G., et al. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res. 66 (2006) 2544-2552
13. Bowman T., Broome M.A., Sinibaldi D., et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 7319-7324
14. Zamo A., Chiarle R., Piva R., et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21 (2002) 1038-1047
15. Niu G., Wright K.L., Huang M., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21 (2002) 2000-2008
16. Darnell Jr. J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2 (2002) 740-749
17. Jing N., and Tweardy D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs 16 (2005) 601-607
18. Yu H., and Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4 (2004) 97-105
19. Aggarwal B.B., Sethi G., Ahn K.S., et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N. Y. Acad. Sci. 1091 (2006) 151-169
20. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., and Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63 (2003) 1270-1279
21. Iwamaru A., Szymanski S., Iwado E., et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26 (2007) 2435-2444
22. Turkson J., Ryan D., Kim J.S., et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276 (2001) 45443-45455
23. Ren Z., Cabell L.A., Schaefer T.S., and McMurray J.S. Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg. Med. Chem. Lett. 13 (2003) 633-636
24. Timofeeva O.A., Gaponenko V., Lockett S.J., et al. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem. Biol. 2 (2007) 799-809
25. Turkson J., Zhang S., Mora L.B., Burns A., Sebti S., and Jove R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem. 280 (2005) 32979-32988
26. Weerasinghe P., Li Y., Guan Y., Zhang R., Tweardy D.J., and Jing N. T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate 68 (2008) 1430-1442
27. Deng J., Grande F., and Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr. Cancer Drug Targets 7 (2007) 91-107
28. Fletcher S., Turkson J., and Gunning P.T. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 3 (2008) 1159-1168
29. Dourlat J., Valentin B., Liu W.Q., and Garbay C. New syntheses of tetrazolylmethylphenylalanine and O-malonyltyrosine as pTyr mimetics for the design of STAT3 dimerization inhibitors. Bioorg. Med. Chem. Lett. 17 (2007) 3943-3946
30. Song H., Wang R., Wang S., and Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 4700-4705
31. Schust J., Sperl B., Hollis A., Mayer T.U., and Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13 (2006) 1235-1242
32. Siddiquee K., Zhang S., and Guida W.C. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 7391-7396
33. Siddiquee K.A., Gunning P.T., and Glenn M. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem. Biol. 2 (2007) 787-798
34. Gunning P.T., Glenn M.P., Siddiquee K.A., et al. Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. ChemBioChem 9 (2008) 2800-2803
35. Wiederkehr-Adam M., Ernst P., Muller K., et al. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3. J. Biol. Chem. 278 (2003) 16117-16128
36. Chao H.G., Bernatowicz M.S., Reiss P.D., and Matsueda G.R. Synthesis and application of bis-silylethyl-derived phosphate-protected Fmoc-phosphotyrosine derivatives for peptide synthesis. J. Org. Chem. 59 (1994) 6687-6691
37. Lohse J., Nielsen P.E., Harrit N., and Dahl O. Fluorescein-conjugated lysine monomers for solid phase synthesis of fluorescent peptides and PNA oligomers. Bioconjug. Chem. 8 (1997) 503-509
38. Shao H., Xu X., and Mastrangelo M.A. Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif. J. Biol. Chem. 279 (2004) 18967-18973
39. Derossi D., Joliot A.H., Chassaing G., and Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269 (1994) 10444-10450
40. Cao X., Tay A., Guy G.R., and Tan Y.H. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol. Cell. Biol. 16 (1996) 1595-1603
41. Bromberg J.F., Horvath C.M., Besser D., Lathem W.W., and Darnell Jr. J.E. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 18 (1998) 2553-2558
42. Hudecz F., Banoczi Z., and Csik G. Medium-sized peptides as built in carriers for biologically active compounds. Med. Res. Rev. 25 (2005) 679-736
43. Shuai K., Horvath C.M., Huang L.H., Qureshi S.A., Cowburn D., Darnell Jr. J.E., et al. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76 (1994) 821-828
44. Dostmann W.R., Taylor M.S., Nickl C.K., Brayden J.E., Frank R., and Tegge W.J. Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 14772-14777
45. Z. Ren, D.R. Coleman, P.K. Mandal, et al, Peptidomimetic inhibitors of Stat3: structure-activity relationships and cellular activity, in: 16th EORTC-NCI-AACR, Symposium on Molecular Targets and Cancer Therapeutics, 2004.